Patient recruitment company, Paradigm, has launched out of stealth, raising USD 203 million in Series A funding. The raise was co-led by Arch Venture Partners and General Catalyst, with participation from other venture capital funds.
The funds raised are to be used to develop its platform and accelerate partnerships with health systems and life sciences companies. Additionally, Paradigm has announced the acquisition of oncology patient recruitment platform, Deep Lens.
Paradigm is a clinical trial technology company seeking to improve the patient recruitment process by integrating healthcare electronic health records with clinical trial recruitment systems. The company seeks to improve the data collection process through automation and AI, making it easier for physicians to maintain records. In terms of monetization, the company will not charge healthcare companies for using the platform; instead, it aims to charge pharmaceutical companies that use the platform to find patients for clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.